Reduction of Suicidality during Clozapine Treatment of Neuroleptic-Resistant Schizophrenia: Impact on Risk-Benefit Assessment

Herbert Y. Meltzer*, Ghadeer Okayli

*Corresponding author for this work

Research output: Contribution to journalArticle

442 Scopus citations

Abstract

Suicide has been reported to occur in 9%-13% of schizophrenic patients. It has been suggested that neuroleptic-resistant or neuroleptic-intolerant schizophrenic patients are at higher risk for suicide than neuroleptic-responsive patients. Clozapine is the treatment of choice for neuroleptic-resistant patients, but its use has been greatly limited because of its ability to cause potentially fatal agranulocytosis. The purpose of this study was to compare the suicidality of neuroleptic-resistant and neuroleptic-responsive patients and to determine if clozapine treatment decreased suicidality in the former group. Method: Prior episodes of suicidality were assessed in a total of 237 neuroleptic-responsive and 184 neuroleptic-resistant patients with schizophrenia or schizoaffective disorder. Eighty-eight of the neuroleptic-resistant patients were treated with clozapine and prospectively evaluated for suicidality for periods of 6 months to 7 years. Results: There was no significant difference in prior suicidal episodes between neuroleptic-responsive and neuroleptic-resistant patients. Clozapine treatment of the neuroleptic-resistant patients during the follow-up period resulted in markedly less suicidality. The number of suicide attempts with a high-probability of success decreased from five to zero. This decrease in suicidality was associated with improvement in depression and hopelessness. Conclusions: These results suggest a basis for reevaluation of the risk-benefit assessment of clozapine, i.e., that the overall morbidity and mortality of patients with neuroleptic-resistant schizophrenia are less with clozapine treatment than with typical neuroleptic drugs because of less suicidality. This conclusion also has implications for increasing the use of clozapine with neuroleptic-responsive patients.

Original languageEnglish (US)
Pages (from-to)183-190
Number of pages8
JournalAmerican Journal of Psychiatry
Volume152
Issue number2
DOIs
StatePublished - Feb 1995

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Reduction of Suicidality during Clozapine Treatment of Neuroleptic-Resistant Schizophrenia: Impact on Risk-Benefit Assessment'. Together they form a unique fingerprint.

  • Cite this